ServareGMP is a new non-profit biotechnology organization formed by long time experts in the field, deeply skilled across industry, with a track record of success across a wide range of programs from discovery through commercialization.
ServareGMP’s mission is to increase deployment of very low-cost biologics medicines including monoclonal antibodies, bi-specific antibodies, fusion proteins, other recombinant proteins, vectors, cell and gene therapies, mRNA-based therapeutics, and vaccine API.
ServareGMP was established to serve populations at risk from:
- Current and Future Outbreaks
- Challenging Bacterial and Fungal Infections
- Parasite-caused Diseases
- Other Unmet Needs of the Displaced and the Vulnerable.
Servare is utilizing cutting edge techniques to drive down the costs of needed medicines so that they are affordable to all.
Introduction
We work in partnership with for-profit organizations, universities, and institutes in flexible ways to bring forward breakthrough technology.
Our founders all have multiple decades of experience in engineering, developing, manufacturing, commercializing and launching biologic medicines resulting in multiple hundreds of program successes.
Our team's track record includes hundreds of programs accomplished. Our two biomanufacturing leaders have +60 biologics developed, manufactured and used in human patients.
We use our expertise in bioprocessing, including high-productivity cell-lines, concentrated fed-batch production, continuous perfusion, continuous purification, GMP manufacturing, and through our nonprofit structure, to do work for the public benefit.
News
New human trials for novel antibody offer hope for immediate protection against deadly Nipah
July 3, 2024 - Oslo, Norway; San Diego, CA, USA - For Immediate Release
Twenty-five years after the first human outbreak of Nipah virus, a novel Nipah monoclonal antibody—which could offer people at risk of infection immediate protection against the deadly disease—is planned to undergo human clinical trials in India and Bangladesh.
These clinical trials will assess the safety and tolerability of a Nipah monoclonal antibody (mAb), a protein that mimics natural antibodies by binding to the virus and preventing infection, which is designed to protect people in Nipah-affected countries from contracting the disease.
With $43.5 million in funding from CEPI, the human trials are intended to commence in 2025, pending regulatory approval. Led by non-profit biotechnology company ServareGMP and supported by Mapp Biopharmaceutical, the trials will assess the Nipah mAb, MBP1F5, in healthy adults at multiple clinical trial sites in India and Bangladesh—two countries that suffer Nipah outbreaks almost every year.
Funding will also support preclinical studies seeking to expand the use of the mAb from pre-exposure prophylaxis (before someone is exposed to a virus) to post-exposure prophylaxis, that is, for people shortly after infection with the virus.
For further information contact: info@servarebiologics.com